Pliant Therapeutics (PLRX) Return on Capital Employed (2020 - 2026)

Pliant Therapeutics (PLRX) has 7 years of Return on Capital Employed data on file, last reported at 58.56% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 58.56%, up 999.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 58.56% (up 999.0% YoY), and the FY2025 annual result was 53.06%, up 114.0% from the prior year.
• Return on Capital Employed rose to 58.56% in Q1 2026 per PLRX's latest filing, from 66.67% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 28.51% in Q2 2023 and troughed at 72.87% in Q2 2025.
• A 5-year average of 50.68% and a median of 52.29% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed tumbled 3310 bps in 2022, then soared 3660 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 37.41% in 2022, then rose by 1 bps to 36.99% in 2023, then slumped by 59 bps to 58.84% in 2024, then dropped by 13 bps to 66.67% in 2025, then advanced by 12 bps to 58.56% in 2026.
• Business Quant data shows PLRX's Return on Capital Employed at 58.56% in Q1 2026, 66.67% in Q4 2025, and 68.78% in Q3 2025.